Tags

Type your tag names separated by a space and hit enter

Economics of an adolescent meningococcal conjugate vaccination catch-up campaign in the United States.
Clin Infect Dis. 2008 Jan 01; 46(1):1-13.CI

Abstract

BACKGROUND

In June 2005, the Advisory Committee on Immunization Practices recommended the newly licensed quadrivalent meningococcal conjugate vaccine for routine use among all US children aged 11 years. A 1-time catch-up vaccination campaign for children and adolescents aged 11-17 years, followed by routine annual immunization of each child aged 11 years, could generate immediate herd immunity benefits. The objective of our study was to analyze the cost-effectiveness of a catch-up vaccination campaign with quadrivalent meningococcal conjugate vaccine for children and adolescents aged 11-17 years.

METHODS

We built a probabilistic model of disease burden and economic impacts for a 10-year period with and without a program of adolescent catch-up meningococcal vaccination, followed by 9 years of routine immunization of children aged 11 years. We used US age- and serogroup-specific surveillance data on incidence and mortality. Assumptions related to the impact of herd immunity were drawn from experience with routine meningococcal vaccination in the United Kingdom. We estimated costs per case, deaths prevented, life-years saved, and quality-adjusted life-years saved.

RESULTS

With herd immunity, the catch-up and routine vaccination program for adolescents would prevent 8251 cases of meningococcal disease in a 10-year period (a 48% decrease). Excluding program costs, this catch-up and routine vaccination program would save US$551 million in direct costs and $920 million in indirect costs, including costs associated with permanent disability and premature death. At $83 per vaccinee, the catch-up vaccination would cost society approximately $223,000 per case averted, approximately $2.6 million per death prevented, approximately $127,000 per life-year saved, and approximately $88,000 per quality-adjusted life-year saved. Targeting counties with a high incidence of disease decreased the cost per life-year saved by two-thirds.

CONCLUSIONS

Although costly, catch-up and routine vaccination of adolescents can have a substantial impact on meningococcal disease burden. Because of herd immunity, catch-up and routine vaccination cost per life-year saved could be up to one-third less than that previously assessed for routine vaccination of children aged 11 years.

Authors+Show Affiliations

National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA. iao8@cdc.govNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

18171206

Citation

Ortega-Sanchez, Ismael R., et al. "Economics of an Adolescent Meningococcal Conjugate Vaccination Catch-up Campaign in the United States." Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America, vol. 46, no. 1, 2008, pp. 1-13.
Ortega-Sanchez IR, Meltzer MI, Shepard C, et al. Economics of an adolescent meningococcal conjugate vaccination catch-up campaign in the United States. Clin Infect Dis. 2008;46(1):1-13.
Ortega-Sanchez, I. R., Meltzer, M. I., Shepard, C., Zell, E., Messonnier, M. L., Bilukha, O., Zhang, X., Stephens, D. S., & Messonnier, N. E. (2008). Economics of an adolescent meningococcal conjugate vaccination catch-up campaign in the United States. Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America, 46(1), 1-13. https://doi.org/10.1086/524041
Ortega-Sanchez IR, et al. Economics of an Adolescent Meningococcal Conjugate Vaccination Catch-up Campaign in the United States. Clin Infect Dis. 2008 Jan 1;46(1):1-13. PubMed PMID: 18171206.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Economics of an adolescent meningococcal conjugate vaccination catch-up campaign in the United States. AU - Ortega-Sanchez,Ismael R, AU - Meltzer,Martin I, AU - Shepard,Colin, AU - Zell,Elizabeth, AU - Messonnier,Mark L, AU - Bilukha,Oleg, AU - Zhang,Xinzhi, AU - Stephens,David S, AU - Messonnier,Nancy E, AU - ,, PY - 2008/1/4/pubmed PY - 2008/2/29/medline PY - 2008/1/4/entrez SP - 1 EP - 13 JF - Clinical infectious diseases : an official publication of the Infectious Diseases Society of America JO - Clin Infect Dis VL - 46 IS - 1 N2 - BACKGROUND: In June 2005, the Advisory Committee on Immunization Practices recommended the newly licensed quadrivalent meningococcal conjugate vaccine for routine use among all US children aged 11 years. A 1-time catch-up vaccination campaign for children and adolescents aged 11-17 years, followed by routine annual immunization of each child aged 11 years, could generate immediate herd immunity benefits. The objective of our study was to analyze the cost-effectiveness of a catch-up vaccination campaign with quadrivalent meningococcal conjugate vaccine for children and adolescents aged 11-17 years. METHODS: We built a probabilistic model of disease burden and economic impacts for a 10-year period with and without a program of adolescent catch-up meningococcal vaccination, followed by 9 years of routine immunization of children aged 11 years. We used US age- and serogroup-specific surveillance data on incidence and mortality. Assumptions related to the impact of herd immunity were drawn from experience with routine meningococcal vaccination in the United Kingdom. We estimated costs per case, deaths prevented, life-years saved, and quality-adjusted life-years saved. RESULTS: With herd immunity, the catch-up and routine vaccination program for adolescents would prevent 8251 cases of meningococcal disease in a 10-year period (a 48% decrease). Excluding program costs, this catch-up and routine vaccination program would save US$551 million in direct costs and $920 million in indirect costs, including costs associated with permanent disability and premature death. At $83 per vaccinee, the catch-up vaccination would cost society approximately $223,000 per case averted, approximately $2.6 million per death prevented, approximately $127,000 per life-year saved, and approximately $88,000 per quality-adjusted life-year saved. Targeting counties with a high incidence of disease decreased the cost per life-year saved by two-thirds. CONCLUSIONS: Although costly, catch-up and routine vaccination of adolescents can have a substantial impact on meningococcal disease burden. Because of herd immunity, catch-up and routine vaccination cost per life-year saved could be up to one-third less than that previously assessed for routine vaccination of children aged 11 years. SN - 1537-6591 UR - https://www.unboundmedicine.com/medline/citation/18171206/Economics_of_an_adolescent_meningococcal_conjugate_vaccination_catch_up_campaign_in_the_United_States_ L2 - https://academic.oup.com/cid/article-lookup/doi/10.1086/524041 DB - PRIME DP - Unbound Medicine ER -